ダウンロード数: 401

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
65_5_171.pdf915.28 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.author島田, 隼人ja
dc.contributor.author佐々木, 裕ja
dc.contributor.author笠井, 奏子ja
dc.contributor.author頴川, 晋ja
dc.contributor.alternativeShimada, Hayatoen
dc.contributor.alternativeSasaki, Hiroshien
dc.contributor.alternativeKasai, Kanakoen
dc.contributor.alternativeEgawa, Shinen
dc.contributor.transcriptionシマダ, ハヤトja-Kana
dc.contributor.transcriptionササキ, ヒロシja-Kana
dc.contributor.transcriptionカサイ, カナコja-Kana
dc.contributor.transcriptionエガワ, シンja-Kana
dc.date.accessioned2019-06-28T00:29:21Z-
dc.date.available2019-06-28T00:29:21Z-
dc.date.issued2019-05-31-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/242273-
dc.description.abstractGonadotropin-releasing hormone (GnRH) agonists play an important role in androgen deprivation therapy (ADT) employed for locally advanced prostate cancer. A 76-year-old man presented with elevated levels of prostate-specific antigen (PSA, 8.33 ng/ml). Subsequently he was diagnosed with cT3bN0M0 prostate cancer, Gleason score 4+5. Before he was referred to our clinic, he had been administered bicalutamide (80 mg/day) daily by the referring physician, followed by subcutaneous injection of goserelin (3. 6 mg) 15 days later. The second dose of another GnRH agonist (leuprolide, 22.5 mg) was administered at his first visit to our clinic, 11 days after goserelin injection, at the discretion of the attending physician (26th day after bicalutamide administration). Bicalutamide administration was concomitantly maintained throughout the period. The patient presented with severe headache the next morning, and imaging studies detected a prominent pituitary adenoma. A trans-sphenoidal surgery was conducted for symptomatic relief. Histopathological analysis revealed a gonadotroph (follicle-stimulating hormone-secreting) pituitary adenoma. Although speculative, repeated injection of GnRH agonist was concluded to be the most likely cause of acute symptomatic gonadotroph pituitary adenoma. The irregular use of medication can cause undesirable and unanticipated adverse events. Awareness is the key to the prevention of such conditions.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.rights許諾条件により本文は2020/06/01に公開ja
dc.subjectPituitary adenomaen
dc.subjectGnRH-agonisten
dc.subjectHeadacheen
dc.subjectProstate canceren
dc.subject.ndc494.9-
dc.titleGnRHアゴニスト再投与後強度の頭痛を来たし, ゴナドトロピン産生下垂体腺腫の関与が疑われた前立腺癌の1例ja
dc.title.alternativeGonadotroph Pituitary Adenoma Causing Severe Headache Following Repeated Use of GnRH Agonist for Prostate Canceren
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume65-
dc.identifier.issue5-
dc.identifier.spage171-
dc.identifier.epage174-
dc.textversionpublisher-
dc.sortkey05-
dc.address東京慈恵会医科大学泌尿器科ja
dc.address東京慈恵会医科大学泌尿器科ja
dc.address東京慈恵会医科大学泌尿器科ja
dc.address東京慈恵会医科大学泌尿器科ja
dc.address.alternativeThe Department of Urology, Jikei University School of Medicineen
dc.address.alternativeThe Department of Urology, Jikei University School of Medicineen
dc.address.alternativeThe Department of Urology, Jikei University School of Medicineen
dc.address.alternativeThe Department of Urology, Jikei University School of Medicineen
dc.identifier.pmid31247696-
dc.identifier.selfDOI10.14989/ActaUrolJap_65_5_171-
dcterms.accessRightsopen access-
datacite.date.available2020-06-01-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.65 No.5

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。